Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma
نویسندگان
چکیده
JDDG: Journal der Deutschen Dermatologischen GesellschaftVolume 19, Issue 9 p. 1341-1345 Clinical LetterOpen Access Adjuvant pembrolizumab-related hyperprogression in stage III melanoma Nadine L. Ammann, Ammann Department of Dermatology and Venereology, Skin Cancer Center Hamburg, University Medical Hamburg-Eppendorf, Germany The first two authors contributed equally to the present article.Search for more papers by this authorGlenn Geidel, Glenn Geidel authorStefan W. Schneider, Stefan Schneider GermanySearch authorChristoffer Gebhardt, Corresponding Author Christoffer Gebhardt [email protected] Correspondence MD Venereology Hamburg-Eppendorf Martinistrasse 52 20251 E-mail: protected]Search author First published: 13 July 2021 https://doi.org/10.1111/ddg.14535 AboutPDF ToolsRequest permissionExport citationAdd favoritesTrack citation ShareShare Give accessShare full text full-text accessPlease review our Terms Conditions Use check box below share version article.I have read accept Wiley Online Library UseShareable LinkUse link a article with your friends colleagues. Learn more.Copy URL Volume19, Issue9September 2021Pages RelatedInformation
منابع مشابه
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
BACKGROUND On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resection of stage III melanoma. METHODS After patients had undergone complete re...
متن کاملAdjuvant ipilimumab in stage III melanoma: New landscape, new questions.
The recently reported significant prolongation of overall survival with ipilimumab as adjuvant in high-risk stage III melanoma patients represents an important event in the adjuvant treatment landscape. The European Organisation for Research and Treatment of Cancer 18071 trial demonstrated a 28% reduction in risk of death in patients treated with ipilimumab at 10 mg/kg (hazard ratio for death, ...
متن کاملPegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
INTRODUCTION Stage III melanoma, also referred to as regional metastatic melanoma, has five-year survival rates ranging between 40% and 78%. In order to reduce the likelihood of recurrence in this high-risk population, patients undergo resection of primary tumors and all involved nodal basins. Systemic therapy is being pursued in an effort to improve outcome data, but the best strategy has yet ...
متن کاملAdjuvant Systemic Therapy in Stage II and III Colon Cancer
The prognosis of colon cancer is primarily determined through staging of the disease. After curative surgery, clinically occult micrometastases are thought to be the major source of disease recurrence. The main aim of postoperative systemic treatment is to eradicate micrometastases, thereby improving outcomes with an increased cure rate. Adjuvant systemic chemotherapy is indicated for patients ...
متن کاملAdjuvant treatment for patients with surgically resected advanced-stage melanoma.
KG The first step is to determine the risk of relapse and death for individual patients. Presently, the factors that guide our risk prediction are the presence or absence of a positive sentinel lymph node, the thickness of the tumor, the mitotic rate, and the presence or absence of ulceration. The current American Joint Committee on Cancer (AJCC) melanoma staging manual, published in 2009 by Ba...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal der Deutschen Dermatologischen Gesellschaft
سال: 2021
ISSN: ['1610-0379', '1610-0387']
DOI: https://doi.org/10.1111/ddg.14535